The drug reviparin is effective in reducing the risk of death following a heart attack and reducing the risk of a subsequent heart attack find researchers according to latest research.
In a study of 15,570 patients resarchers evaluated the effects of reviparin on the composite outcome of death, heart attack, and stroke at seven and 30 days. Researchers found total mortality was reduced from 11 percent of patients in the placebo group to 9.6 percent in the reviparin group a 13-percent lowered risk. Benefits were still seen at 30 days with significant reductions in death rate and significantly lower numbers of additional heart attacks however no significant differences were observed for strokes.
In conclusion researchers say Reviparin is considerably less expensive than other antithrombotic agents, and Its use is relatively straightforward and can be used in both developed and developing countries hence researchers urge the use of the drug .